Global merger and acquisition activity hit $3.9 trillion in 2019, according to Refinitiv.
Why it matters: That represents a 3% decrease from 2018, but was still the fourth-largest dollar volume in history and sixth straight year above $3 trillion.
- Record-high stock markets and laughably-low interest rates proved more compelling than rising regulatory, geopolitical, and trade uncertainties.
Activity was driven by mega-deals, or transactions valued at more than $10 billion.
- Mega-deals represented 31% of the global total, a sizable jump from 2018 and the largest-such percentage since 2015 (the busiest-ever year for M&A).
- This trend also is reflected in how the number of deals decreased 5% year-over-year, and represented a 3-year low.
U.S. deal activity was another upward driver, hitting $1.8 trillion.
- That's a 6% rise over 2018, and includes 15 of the year's 20 largest announced transactions.
- The year's largest deal was in the U.S. healthcare sector (+26% year-over-year), with Bristol-Myers Squibb buying Celgene for $74 billion.
Europe and Asia-Pacific (ex-Japan) volume fell 25% and 14%, respectively.
- Cross-border deals were off 25%, hitting its lowest volume in five years.
The bottom line: 2019 was bolstered by a busy fourth quarter, and it wouldn't be surprising to see that extend a bit into 2020. But then all bets are off — particularly in a presidential election year that could cause some bulls to slow their stampede.
Go deeper: Anti-trust uncertainty is the new normal for dealmakers
